Search / Trial NCT00000950

Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Trial Information

Current as of October 18, 2024

Completed

Keywords

Tuberculosis Isoniazid Pyrazinamide Pyridoxine Rifampin Aids Related Opportunistic Infections Drug Therapy, Combination Ethambutol Acquired Immunodeficiency Syndrome Antitubercular Agents

Description

Patients receive up to 8 weeks of two or more anti-tuberculosis drugs, of which at least two are isoniazid, rifampin, pyrazinamide, or ethambutol. Blood specimens are collected at 2, 6, and 10 hours after administration of study medication, once between Days 10 and 14 of a phase of daily treatment and once while on an intermittent dose regimen (twice weekly or three times weekly).

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • You may be eligible for this study if you:
  • * Are HIV-positive and have tuberculosis.
  • * Are 13 years of age or older.
  • * Have written, informed consent of parent or guardian if you are under 18 years of age.
  • * Agree to practice abstinence or use barrier methods of birth control during the study.
  • Exclusion Criteria
  • You will not be eligible for this study if you:
  • * Have any other disorder or condition which might cause study treatment to be undesirable.
  • * Are pregnant.

About National Institute Of Allergy And Infectious Diseases (Niaid)

The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.

Locations

Los Angeles, California, United States

New York, New York, United States

New York, New York, United States

Torrance, California, United States

Honolulu, Hawaii, United States

Honolulu, Hawaii, United States

Brooklyn, New York, United States

Cleveland, Ohio, United States

Philadelphia, Pennsylvania, United States

New Orleans, Louisiana, United States

Atlanta, Georgia, United States

New York, New York, United States

Miami, Florida, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0